Paul Josephs - 08 Jul 2025 Form 4 Insider Report for LIFECORE BIOMEDICAL, INC. \DE\ (LFCR)

Role
Chief Executive Officer, Director
Signature
/s/ Aaron S. Perlitsh, Attorney-In-Fact for Paul Josephs
Issuer symbol
LFCR
Transactions as of
08 Jul 2025
Transactions value $
-$449,279
Form type
4
Filing time
10 Jul 2025, 16:41:00 UTC
Previous filing
22 May 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Josephs Paul Chief Executive Officer, Director C/O LIFECORE BIOMEDICAL, INC., 3515 LYMAN BLVD., CHASKA /s/ Aaron S. Perlitsh, Attorney-In-Fact for Paul Josephs 10 Jul 2025 0002022547

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LFCR Common Stock Options Exercise +150K +27.87% 688K 08 Jul 2025 Direct F1, F2
transaction LFCR Common Stock Tax liability -$449K -54.9K -7.97% $8.19 633K 08 Jul 2025 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LFCR Performance-Based Restricted Stock Units Options Exercise -150K -10% 1.35M 08 Jul 2025 Common Stock 150K Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The performance-based restricted stock units vested based on the Issuer's achievement of a stock price milestone.
F2 Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's common stock upon the Issuer's common stock achieving certain stock prices.
F3 Represents number of shares withheld by the issuer to satisfy applicable tax withholding obligations in connection with the vesting and settlement of the performance stock unit award as reported in Table I.